Guinea
Tuberculosis profile
| High HIV burden |
Population  2013 12 million
Estimates of TB burden * 2013 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) 3.2 (2–4.3) 27 (17–37)
Mortality (HIV+TB only) 1.7 (1.3–2.2) 14 (11–19)
Prevalence  (includes HIV+TB) 29 (16–45) 244 (133–387)
Incidence  (includes HIV+TB) 21 (18–23) 177 (157–199)
Incidence (HIV+TB only) 5.1 (4.8–6.1) 43 (41–52)
Case detection, all forms (%) 54 (48–61)    
Estimates of MDR-TB burden * 2013   New   Retreatment
% of TB cases with MDR-TB 0.6 (0.1–1.6) 28 (14–47)
MDR-TB cases among notified pulmonary
TB cases
50 (8–130) 140 (71–240)
TB case notifications 2013 New ** Relapse
Pulmonary, bacteriologically confirmed 6 954   485
Pulmonary, clinically diagnosed 1 441   31
Extrapulmonary 2 382   20
       
Total new and relapse 11 313    
Previously treated, excluding relapses 0    
Total cases notified 11 313    
Among 11 313 new and relapse cases:
185 (2%) cases aged under 15 years; male:female ratio: 1.7
Reported cases of RR-/MDR-TB 2013 New Retreatment Total **
Cases tested for RR-/MDR-TB 7 (<1%) 66 (12%) 105
Laboratory-confirmed RR-/MDR-TB cases     167
Patients started on MDR-TB treatment     48
TB/HIV 2013 Number (%)
TB patients with known HIV status 8 444 (75)
HIV-positive TB patients 1 959 (23)
HIV-positive TB patients on co-trimoxazole preventive therapy (CPT) 1 786 (91)
HIV-positive TB patients on antiretroviral therapy (ART) 1 534 (78)
HIV-positive people screened for TB    
HIV-positive people provided with IPT    
Treatment success rate (%)
New and relapse cases registered in 2012 82
Previously treated cases, excluding relapse, registered in 2012  
HIV-positive TB cases, all types, registered in 2012 80
RR-/MDR-TB cases started on second-line treatment in 2011 7
XDR-TB cases started on second-line treatment in 2011  
Laboratories 2013  
Smear (per 100 000 population) 0.5
Culture (per 5 million population) 0.4
Drug susceptibility testing (per 5 million population) 0.4
Sites performing Xpert MTB/RIF 1
Is second-line drug susceptibility testing available? Yes, in and outside
country
Financing TB control 2014  
National TB programme budget (US$ millions) 8.1
% Funded domestically 19%
% Funded internationally 59%
% Unfunded 22%
* Ranges represent uncertainty intervals
** Includes cases with unknown previous TB treatment history
***
(Rate per 100 000 population per year)
Mortality graph
   Mortality  (excludes HIV+TB)

(Rate per 100 000 population)
Prevalence graph
   Prevalence

(Rate per 100 000 population per year)
Incidence graph
   Notified (new and relapse)   Incidence
   Incidence (HIV+TB only)

(Number of patients)
CPT ART graph
   HIV-positive TB patients
   on CPT   on ART

Treatment success rate (%)
tx success graph
   New   Retreatment
   New and relapse   Retreatment, excluding
relapse
   HIV-positive   RR-/MDR-TB   XDR-TB

Total budget (US$ millions)
Budget funding Graph
__Funded domestically__Funded internationally
__Unfunded
 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 Generated: 2015-07-08 Data: www.who.int/tb/data